# Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
Canonical URL: https://biopharmsignal.com/news/ANL/adlai-nortye-announces-140-0-million-private-placement-equity-financing
Ticker: ANL
Company: Adlai Nortye Ltd.
Source: Adlai Nortye Ltd.
Published: 2026-02-03 12:00 EST
Original Source URL: https://ir.adlainortye.com
## Summary

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into

## Article Body
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into
## Recent Company News
- 2026-07-16 11:00 EST — [Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025](https://biopharmsignal.com/news/ANL/adlai-nortye-announces-first-patient-dosed-in-intermittent-weekly-dosing-arm-of--5ee3e1aa) — Source: Adlai Nortye Ltd.
- 2026-07-13 11:00 EST — [Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists](https://biopharmsignal.com/news/ANL/adlai-nortye-expands-scientific-advisory-board-with-appointment-of-two-leading-m-704804d4) — Source: Adlai Nortye Ltd.
- 2026-04-16 10:59 EST — [Adlai Nortye Announces $150.0 Million Private Placement Equity Financing](https://biopharmsignal.com/news/ANL/adlai-nortye-announces-150-0-million-private-placement-equity-financing) — Source: Adlai Nortye Ltd.
- 2026-03-03 07:00 EST — [Adlai Nortye to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ANL/adlai-nortye-to-participate-in-upcoming-investor-conferences) — Source: Adlai Nortye Ltd.
- 2026-02-12 09:00 EST — [Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations](https://biopharmsignal.com/news/ANL/adlai-nortye-announces-first-patient-enrolled-in-global-phase-1-trial-of-pan-ras-on-inhibitor-an9025-for-solid-tumors-harboring-ras-mutations) — Source: Adlai Nortye Ltd.
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)